Lecanemab Clinical Trials (2026): 18 Studies for Alzheimer's Disease & Dementia
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
18 Lecanemab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 9 indications (including Alzheimer's Disease & Dementia) and 6,369 total planned enrollment. 4 Phase 3 Lecanemab trials and 3 Phase 2 are listed. 8 Lecanemab clinical trials are actively recruiting at 1 U.S. site across 1 state. Most recent activity: NCT04468659 (Jan 2031).
Where to Participate: All Lecanemab Trial Sites in the U.S. (1 site across 1 state)
Every actively recruiting Lecanemabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT05925621 | Map |
Lecanemab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | enrolling by invitation | completed | not yet recruiting | Total |
|---|---|---|---|---|---|---|
| Early P1 | 1 | 1 | ||||
| P1 | 2 | 2 | ||||
| P2 | 1 | 1 | 1 | 3 | ||
| P2/P3 | 2 | 2 | ||||
| P3 | 1 | 3 | 4 | |||
| N/A | 3 | 1 | 2 | 6 |
Recruiting Lecanemab clinical trials (8)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07212062 | The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab. | P2 | Alzheimers Disease | 60 | Dec 2025 |
| NCT07152418 | Therapeutic Efficacy of Monoclonal Antibody Drugs for Alzheimer's Disease Based on PET Research | — | Alzheimer Disease (AD) | 120 | Sep 2025 |
| NCT06285448 | Feasibility of Lecanemab Registry and Clinical Outcome Measures | — | Alzheimer Disease | 20 | Jan 2024 |
| NCT05925621 | Cognitive Neurology Unit Clinical Registry | — | Alzheimer Disease | 500 | Jul 2023 |
| NCT07505095 | ADEfficacy of Lecanemab at Different Therapeutic Doses for Alzheimer's Disease (AD) in Real-World Practice | — | Alzheimer Disease (AD) | 140 | Apr 2026 |
| NCT06741553 | Prospective Cohort Study of Patients With Early Alzheimer's Disease Treated With Lecanemab | — | Alzheimer Disease | 120 | Jun 2024 |
| NCT06871839 | The Clinical Study of Synaptic Plasticity-based Lencanumab for the Treatment of Early Alzheimer's Disease | — | Alzheimer's Disease | 120 | Mar 2025 |
| NCT06530732 | Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study (DIVA Study) | P3 | Alzheimer's Disease | 60 | Jul 2024 |
Lecanemab clinical trials by indication
Alzheimer's Disease (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06384573 | DIAN-TU | P3 | active not recruiting | DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease |
| NCT06602258 | — | P2 | active not recruiting | A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease |
| NCT06530732 | — | P3 | recruiting | Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study (DIVA Study) |
| NCT01767311 | — | P2 | completed | A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease |
Alzheimers Disease (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07212062 | — | P2 | not yet recruiting | The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab. |
| NCT05269394 | DIAN-TU | P2/P3 | active not recruiting | Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) |
| NCT01760005 | DIAN-TU | P2/P3 | active not recruiting | Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 |
Alzheimer Disease (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06285448 | — | N/A | enrolling by invitation | Feasibility of Lecanemab Registry and Clinical Outcome Measures |
| NCT05925621 | — | N/A | recruiting | Cognitive Neurology Unit Clinical Registry |
| NCT06741553 | — | N/A | recruiting | Prospective Cohort Study of Patients With Early Alzheimer's Disease Treated With Lecanemab |
Alzheimer Disease (AD) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07152418 | — | N/A | not yet recruiting | Therapeutic Efficacy of Monoclonal Antibody Drugs for Alzheimer's Disease Based on PET Research |
| NCT07505095 | AD | N/A | not yet recruiting | Efficacy of Lecanemab at Different Therapeutic Doses for Alzheimer's Disease (AD) in Real-World Practice |
Healthy Volunteers (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05533801 | AI | P1 | completed | A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants |
| NCT05045716 | — | P1 | completed | A Study of Subcutaneous Lecanemab in Healthy Participants |
Alzheimer's Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06871839 | — | N/A | recruiting | The Clinical Study of Synaptic Plasticity-based Lencanumab for the Treatment of Early Alzheimer's Disease |
Mild Cognitive Impairment (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05469009 | — | Early P1 | active not recruiting | Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy |
Preclinical Alzheimer's Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04468659 | — | P3 | active not recruiting | AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid |
Early Alzheimer's Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03887455 | Clarity AD | P3 | active not recruiting | A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease |
Lecanemab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| DIAN-TU | NCT06384573 | P3 | active not recruiting | Alzheimer's Disease | 40 | — |
| Clarity AD | NCT03887455 | P3 | active not recruiting | Early Alzheimer's Disease | 1,906 | — |
All Lecanemab trials (18)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT04468659 | AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid | P3 | active not recruiting | 1,400 | Eisai Inc. | Jul 2020 | |
| NCT06384573 | DIAN-TU | DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease | P3 | active not recruiting | 40 | Washington University School of Medicine | Jun 2024 |
| NCT05469009 | Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy | Early P1 | active not recruiting | 15 | Ali Rezai | Jul 2022 | |
| NCT03887455 | Clarity AD | A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | P3 | active not recruiting | 1,906 | Eisai Inc. | Mar 2019 |
| NCT07212062 | The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab. | P2 | not yet recruiting | 60 | Neurology Office of South Florida | Dec 2025 | |
| NCT07152418 | Therapeutic Efficacy of Monoclonal Antibody Drugs for Alzheimer's Disease Based on PET Research | — | not yet recruiting | 120 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Sep 2025 | |
| NCT05269394 | DIAN-TU | Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) | P2/P3 | active not recruiting | 197 | Washington University School of Medicine | Dec 2021 |
| NCT01760005 | DIAN-TU | Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 | P2/P3 | active not recruiting | 490 | Washington University School of Medicine | Dec 2012 |
| NCT06285448 | Feasibility of Lecanemab Registry and Clinical Outcome Measures | — | enrolling by invitation | 20 | HealthPartners Institute | Jan 2024 | |
| NCT05925621 | Cognitive Neurology Unit Clinical Registry | — | recruiting | 500 | Beth Israel Deaconess Medical Center | Jul 2023 | |
| NCT07505095 | AD | Efficacy of Lecanemab at Different Therapeutic Doses for Alzheimer's Disease (AD) in Real-World Practice | — | not yet recruiting | 140 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Apr 2026 |
| NCT06602258 | A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease | P2 | active not recruiting | 105 | Eisai Inc. | Sep 2024 | |
| NCT06741553 | Prospective Cohort Study of Patients With Early Alzheimer's Disease Treated With Lecanemab | — | recruiting | 120 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Jun 2024 | |
| NCT06871839 | The Clinical Study of Synaptic Plasticity-based Lencanumab for the Treatment of Early Alzheimer's Disease | — | recruiting | 120 | Cuibai Wei，Clinical Professor | Mar 2025 | |
| NCT06530732 | Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study (DIVA Study) | P3 | recruiting | 60 | Zhejiang Provincial People's Hospital | Jul 2024 | |
| NCT01767311 | A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease | P2 | completed | 856 | Eisai Inc. | Dec 2012 | |
| NCT05533801 | AI | A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants | P1 | completed | 160 | Eisai Inc. | Sep 2022 |
| NCT05045716 | A Study of Subcutaneous Lecanemab in Healthy Participants | P1 | completed | 60 | Eisai Inc. | Sep 2021 |
Lecanemab clinical trials: frequently asked questions
- How many Lecanemab clinical trials are there?
- 18 Lecanemab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are actively recruiting participants. 3 are marked completed.
- Are Lecanemab clinical trials recruiting in 2026?
- Yes — 5 Lecanemab trials are actively recruiting in 2026, with 1 U.S. site across 1 state. See the recruiting trials and the per-state site list further down this page.
- What conditions is Lecanemab being studied for?
- Lecanemab is being studied for Alzheimer's Disease, Dementia, Alzheimer Disease, Alzheimers Disease, Alzheimer Disease (AD) and 14 more. The trials are grouped by indication on this page.
- What phase is Lecanemab in?
- Lecanemab clinical trials span 4 Phase 3, 3 Phase 2, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Lecanemab clinical trials?
- The lead sponsor across the most Lecanemab trials is Eisai Inc., with 8 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Lecanemabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: